Z51.11 Código facturable y específico Encounter for antineoplastic chemotherapy
ICD-10-CM Z51.11 identifies “Encounter for antineoplastic chemotherapy” as a billable/specific code in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.
Capítulo 21: Factors influencing health status and contact with health services
Exento de informar presencia al ingreso
Instrucciones del código
Sin notas adicionales.
Instrucciones de niveles superiores
Capítulos 21 · Factors influencing health status and contact with health services (Z00-Z99)
Note3
- Z codes represent reasons for encounters. A corresponding procedure code must accompany a Z code if a procedure is performed. Categories Z00-Z99 are provided for occasions when circumstances other than a disease, injury or external cause classifiable to categories A00-Y89 are recorded as 'diagnoses' or 'problems'. This can arise in two main ways:
- (a) When a person who may or may not be sick encounters the health services for some specific purpose, such as to receive limited care or service for a current condition, to donate an organ or tissue, to receive prophylactic vaccination (immunization), or to discuss a problem which is in itself not a disease or injury.
- (b) When some circumstance or problem is present which influences the person's health status but is not in itself a current illness or injury.
Z40-Z53 · Encounters for other specific health care (Z40-Z53)
Inclusion terms1
Categories Z40-Z53 are intended for use to indicate a reason for care. They may be used for patients who have already been treated for a disease or injury, but who are receiving aftercare or prophylactic care, or care to consolidate the treatment, or to deal with a residual state
Excludes 21
follow-up examination for medical surveillance after treatment (Z08-Z09)
Z51 · Encounter for other aftercare and medical care
Excludes 11
follow-up examination after treatment (Z08-Z09)
Code also1
condition requiring care
Z51.1 · Encounter for antineoplastic chemotherapy and immunotherapy
Excludes 21
encounter for chemotherapy and immunotherapy for nonneoplastic condition - code to condition
Referencias del índice oficial
Referencias del índice oficial (4)
Chemotherapy(session) (for) (2)
- Chemotherapy(session) (for) › cancerÍndice de enfermedades
- Chemotherapy(session) (for) › neoplasmÍndice de enfermedades
Encounter(with health service) (for) (1)
- Encounter(with health service) (for) › chemotherapy for neoplasmÍndice de enfermedades
Maintenance(encounter for) (1)
- Maintenance(encounter for) › antineoplastic chemotherapyÍndice de enfermedades
Historial
Historial del código
Sin cambios desde la primera aparición
Vigente desde
- Primera aparición
Encounter for antineoplastic chemotherapy
Código de diagnóstico facturable
CDC/NCHS · FY2016Todas las ediciones (19)
| Todas las ediciones | Vigente desde | Historial del código |
|---|---|---|
| FY2016 | 2015-10-01 | Primera aparición |
| FY2017 | 2016-10-01 | Sin cambios tabulares |
| FY2018 | 2017-10-01 | Sin cambios tabulares |
| FY2019 | 2018-10-01 | Sin cambios tabulares |
| FY2020 | 2019-10-01 | Sin cambios tabulares |
| FY2020 · April | 2020-04-01 | Sin cambios tabulares |
| FY2021 | 2020-10-01 | Sin cambios tabulares |
| FY2021 · 01-01 | 2021-01-01 | Sin cambios tabulares |
| FY2022 | 2021-10-01 | Sin cambios tabulares |
| FY2022 · 04-01 | 2022-04-01 | Sin cambios tabulares |
| FY2023 | 2022-10-01 | Sin cambios tabulares |
| FY2023 · 04-01 | 2023-04-01 | Sin cambios tabulares |
| FY2024 | 2023-10-01 | Sin cambios tabulares |
| FY2024 · 04-01 | 2024-04-01 | Sin cambios tabulares |
| FY2025 | 2024-10-01 | Sin cambios tabulares |
| FY2025 · 04-01 | 2025-04-01 | Sin cambios tabulares |
| FY2026 | 2025-10-01 | Sin cambios tabulares |
| FY2026 · April | 2026-04-01 | Sin cambios tabulares |
| FY2027 | 2026-10-01 | Sin cambios tabulares |
Correspondencias históricas ICD-9 · 2018
Solo correspondencia histórica; no sustituye códigos automáticamente.
- V58.11
Esta entrada es un código completo en la edición seleccionada. La comprobación del catálogo no establece la pertinencia clínica ni garantiza el reembolso.